These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
731 related articles for article (PubMed ID: 11932303)
1. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303 [TBL] [Abstract][Full Text] [Related]
2. Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly. Parkinson C; Drake WM; Wieringa G; Yates AP; Besser GM; Trainer PJ Clin Endocrinol (Oxf); 2002 Mar; 56(3):303-11. PubMed ID: 11940041 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061 [TBL] [Abstract][Full Text] [Related]
4. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586 [TBL] [Abstract][Full Text] [Related]
5. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. Lindberg-Larsen R; Møller N; Schmitz O; Nielsen S; Andersen M; Orskov H; Jørgensen JO J Clin Endocrinol Metab; 2007 May; 92(5):1724-8. PubMed ID: 17341562 [TBL] [Abstract][Full Text] [Related]
6. The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly. Parkinson C; Whatmore AJ; Yates AP; Drake WM; Brabant G; Clayton PE; Trainer PJ Clin Endocrinol (Oxf); 2003 Aug; 59(2):168-74. PubMed ID: 12864793 [TBL] [Abstract][Full Text] [Related]
7. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. Parkinson C; Kassem M; Heickendorff L; Flyvbjerg A; Trainer PJ J Clin Endocrinol Metab; 2003 Dec; 88(12):5650-5. PubMed ID: 14671148 [TBL] [Abstract][Full Text] [Related]
8. Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant. Drake WM; Loureiro RA; Parkinson C; Monson JP; Besser GM; Trainer PJ Eur J Endocrinol; 2005 Jan; 152(1):47-51. PubMed ID: 15762186 [TBL] [Abstract][Full Text] [Related]
9. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly. Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168 [TBL] [Abstract][Full Text] [Related]
10. The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment. Roemmler J; Steffin B; Gutt B; Schneider HJ; Sievers C; Bidlingmaier M; Schopohl J Growth Horm IGF Res; 2010 Oct; 20(5):338-44. PubMed ID: 20598600 [TBL] [Abstract][Full Text] [Related]
11. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. Higham CE; Atkinson AB; Aylwin S; Bidlingmaier M; Drake WM; Lewis A; Martin NM; Moyes V; Newell-Price J; Trainer PJ J Clin Endocrinol Metab; 2012 Apr; 97(4):1187-93. PubMed ID: 22278424 [TBL] [Abstract][Full Text] [Related]
15. [Lowered ghrelin levels in acromegaly—normalization after treatment]. Kozakowski J; Rabijewski M; Zgliczyński W Endokrynol Pol; 2005; 56(6):862-70. PubMed ID: 16821203 [TBL] [Abstract][Full Text] [Related]
16. Effects of a growth hormone receptor antagonist on bone markers in acromegaly. Fairfield WP; Sesmilo G; Katznelson L; Pulaski K; Freda PU; Stavrou S; Kleinberg D; Klibanski A Clin Endocrinol (Oxf); 2002 Sep; 57(3):385-90. PubMed ID: 12201832 [TBL] [Abstract][Full Text] [Related]
17. Acute effect of pegvisomant on cardiovascular risk markers in healthy men: implications for the pathogenesis of atherosclerosis in GH deficiency. Muller AF; Leebeek FW; Janssen JA; Lamberts SW; Hofland L; van der Lely AJ J Clin Endocrinol Metab; 2001 Nov; 86(11):5165-71. PubMed ID: 11701672 [TBL] [Abstract][Full Text] [Related]
18. Inflammatory cardiovascular risk markers in women with hypopituitarism. Sesmilo G; Miller KK; Hayden D; Klibanski A J Clin Endocrinol Metab; 2001 Dec; 86(12):5774-81. PubMed ID: 11739438 [TBL] [Abstract][Full Text] [Related]
19. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men. Veldhuis JD; Bidlingmaier M; Anderson SM; Wu Z; Strasburger CJ J Clin Endocrinol Metab; 2001 Jul; 86(7):3304-10. PubMed ID: 11443205 [TBL] [Abstract][Full Text] [Related]
20. Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly. Trainer PJ; Drake WM; Perry LA; Taylor NF; Besser GM; Monson JP J Clin Endocrinol Metab; 2001 Jul; 86(7):2989-92. PubMed ID: 11443156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]